Vulnerability of invasive glioblastoma cells to lysosomal membrane destabilization

Vulnerability of invasive glioblastoma cells to lysosomal membrane destabilization

Abstract The current clinical care of glioblastomas leaves behind invasive, radio‐ and chemo‐resistant cells. We recently identified mammary‐derived growth inhibitor (MDGI/FABP3) as a biomarker for invasive gliomas. Here, we demonstrate a novel function for MDGI in the maintenance of lysosomal membr...

Full description

Bibliographic Details
Main Authors: Vadim Le Joncour, Pauliina Filppu, Maija Hyvönen, Minna Holopainen, S Pauliina Turunen, Harri Sihto, Isabel Burghardt, Heikki Joensuu, Olli Tynninen, Juha Jääskeläinen, Michael Weller, Kaisa Lehti, Reijo Käkelä, Pirjo Laakkonen
Format: Article
Language:English
Published: Wiley 2019-06-01
Series:EMBO Molecular Medicine
Subjects:
antihistamine
glioma
LMP
MDGI
PUFA
Online Access:https://doi.org/10.15252/emmm.201809034

Internet

https://doi.org/10.15252/emmm.201809034

Similar Items